Furthermore, the presence of p53 mutations has a cooperative effect on KRAS mutations [88,89] and PI3K pathway mutations in adenocarcinoma can coexist with KRAS mutations [90] and are commonly associated with tyrosine kinase inhibitor and immune checkpoint inhibitor resistance [40,41]. This evidence concerns the gene KRAS and adenocarcinoma.